Payment overview · 2025
General Payments
$580.15
25 reported records · 8 companies
Healthcare provider profile · identity verified
Ferid Osmanovic, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ASTORIA, NY · NPI 1992976385
Verified facts
What the public records show
CMS Open Payments records show Ferid Osmanovic, MD received $580.15 in general payments during 2025 across 25 reported records.
ABBVIE INC. accounted for 38.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexium by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $224.52 | 38.7% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $193.88 | 33.4% | 9 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $34.21 | 5.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.31 | 5.7% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.24 | 5.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22.29 | 3.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.63 | 3.7% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$20.07 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $580.15 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $181.68 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $72.35 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $60.78 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $60.75 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.47 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $34.21 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $34.03 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $33.31 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $33.31 | 2 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $30.24 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 97 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 31 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
59 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 494 | 165 |
| Amlodipine Besylate | Amlodipine Besylate | 426 | 146 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 378 | 143 |
| Metoprolol Succinate | Metoprolol Succinate | 301 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 254 | 89 |
| Metformin Hcl | Metformin Hcl | 253 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 252 | 70 |
| Diclofenac Sodium | Diclofenac Sodium | 211 | 59 |
| Losartan Potassium | Losartan Potassium | 204 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 176 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 174 | 57 |
| Omeprazole | Omeprazole | 167 | 57 |
| Gabapentin | Gabapentin | 148 | 46 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 144 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 55 |
| Furosemide | Furosemide | 121 | 41 |
| Simvastatin | Simvastatin | 119 | 41 |
| Trazodone Hcl | Trazodone Hcl | 118 | 44 |
| Vascepa | Icosapent Ethyl | 111 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 31 |
| Azithromycin | Azithromycin | 104 | 73 |
| Jardiance | Empagliflozin | 99 | 32 |
| Eliquis | Apixaban | 97 | 33 |
| Allopurinol | Allopurinol | 96 | 28 |
| Ibuprofen | Ibuprofen | 96 | 35 |
| Lisinopril | Lisinopril | 95 | 34 |
| Montelukast Sodium | Montelukast Sodium | 95 | 37 |
| Fenofibrate | Fenofibrate Nanocrystallized | 93 | 25 |
| Lidocaine | Lidocaine | 91 | 23 |
| Januvia | Sitagliptin Phosphate | 90 | 20 |
| Famotidine | Famotidine | 88 | 32 |
| Finasteride | Finasteride | 88 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 26 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 78 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 26 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 69 | 27 |
| Metformin Hcl Er | Metformin Hcl | 68 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 36 |
| Ezetimibe | Ezetimibe | 63 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 40 |
| Linzess | Linaclotide | 59 | 23 |
| Mupirocin | Mupirocin | 57 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 15 |
| Alendronate Sodium | Alendronate Sodium | 49 | 18 |
| Ozempic | Semaglutide | 49 | 15 |
| Ramipril | Ramipril | 49 | 14 |
| Carvedilol | Carvedilol | 46 | 19 |
| Potassium Chloride | Potassium Chloride | 46 | 17 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 45 | 11 |
| Meclizine Hcl | Meclizine Hcl | 45 | 23 |
| Meloxicam | Meloxicam | 45 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 17 |
| Glimepiride | Glimepiride | 42 | suppressed |
| Atenolol | Atenolol | 40 | 13 |
| Donepezil Hcl | Donepezil Hcl | 40 | 13 |
| Valsartan | Valsartan | 40 | 12 |
| Enalapril Maleate | Enalapril Maleate | 39 | 12 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Glipizide Er | Glipizide | 38 | 11 |
| Synthroid | Levothyroxine Sodium | 38 | 13 |
| Acyclovir | Acyclovir | 37 | suppressed |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | 12 |
| Ammonium Lactate | Ammonium Lactate | 36 | 15 |
| Naproxen | Naproxen | 36 | 17 |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | 16 |
| Repaglinide | Repaglinide | 33 | 11 |
| Azelastine Hcl | Azelastine Hcl | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 23 |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Procto-Med Hc | Hydrocortisone | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 30 | suppressed |
| Restasis | Cyclosporine | 30 | suppressed |
| Norgesic Forte | Orphenadrine/Aspirin/Caffeine | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 28 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Zileuton Er | Zileuton | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 20 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 26 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Folic Acid | Folic Acid | 23 | 12 |
| Lokelma | Sodium Zirconium Cyclosilicate | 23 | suppressed |
| Clotrimazole | Clotrimazole | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | 12 |
| Ciclopirox | Ciclopirox | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Adapalene | Adapalene | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 14 |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Klor-Con M10 | Potassium Chloride | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Jublia | Efinaconazole | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Edarbi | Azilsartan Medoxomil | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Multaq | Dronedarone Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Tavaborole | Tavaborole | 13 | suppressed |
| Toprol Xl | Metoprolol Succinate | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 12 | suppressed |
| Pimecrolimus | Pimecrolimus | 12 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Triazolam | Triazolam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $580.15 · 25 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AMVUTTRA, BOTOX, BREZTRI, COMIRNATY, ELIQUIS, EVENITY, FARXIGA, MINIMED 780G, MOUNJARO, PREVNAR 20, PROLIA, QULIPTA, UBRELVY, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error